Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rentokil
RTO
|
+$514M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$210M |
| 3 |
TFI International
TFII
|
+$145M |
| 4 |
Ambev
ABEV
|
+$142M |
| 5 |
Vanguard S&P 500 ETF
VOO
|
+$133M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$8.38B |
| 2 |
Apple
AAPL
|
+$5.7B |
| 3 |
Amazon
AMZN
|
+$3.72B |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$3.64B |
| 5 |
Mastercard
MA
|
+$3.47B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.11% |
| 2 | Healthcare | 21.42% |
| 3 | Financials | 11.42% |
| 4 | Industrials | 10.73% |
| 5 | Consumer Discretionary | 10.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
SPX Corp
SPXC
$9.4B
| $39.2M | 0.03% |
596,492
-768,070
| -56% | -$50.3M |
|
427
Alcon
ALC
$34B
| $39M | 0.03% |
570,795
-486,387
| -46% | -$31M |
|
428
Unifirst Corp
UNF
$5.45B
| $38.5M | 0.03% |
199,609
-291,575
| -59% | -$53.3M |
|
429
UBS Group
UBS
$170B
| $38.3M | 0.03% |
2,059,828
-2,378,200
| -54% | -$40.4M |
|
430
Stride
LRN
$4.15B
| $38.2M | 0.03% |
1,222,312
-1,205,874
| -50% | -$44.3M |
|
431
Vontier
VNT
$4.54B
| $38M | 0.03% |
1,967,030
-1,425,486
| -42% | -$26.7M |
|
|
CSW
432
CSW Industrials
CSW
$4.44B
| $37.8M | 0.03% |
325,694
-319,120
| -49% | -$38.2M |
|
433
Embecta
EMBC
$219M
| $37.6M | 0.03% |
1,487,804
-1,542,828
| -51% | -$47.1M |
|
434
Ambarella
AMBA
$3.04B
| $37.5M | 0.03% |
456,390
-658,278
| -59% | -$43.8M |
|
435
Otis Worldwide
OTIS
$27.9B
| $37.4M | 0.03% |
477,773
-1,342,323
| -74% | -$99.1M |
|
|
WIRE
436
DELISTED
Encore Wire Corp
WIRE
| $37.4M | 0.03% |
272,035
-330,941
| -55% | -$45.8M |
|
437
Fulton Financial
FULT
$4.68B
| $37.4M | 0.03% |
2,220,903
-2,068,759
| -48% | -$36.3M |
|
438
Sunstone Hotel Investors
SHO
$2.19B
| $36.8M | 0.03% |
3,812,641
-5,181,927
| -58% | -$53.6M |
|
439
Chemed
CHE
$7.16B
| $36.8M | 0.03% |
72,024
-111,230
| -61% | -$54.1M |
|
440
Citizens Financial Group
CFG
$30.1B
| $36.7M | 0.03% |
931,584
-1,337,342
| -59% | -$52.2M |
|
441
Halozyme
HALO
$9.88B
| $36.7M | 0.03% |
644,142
-734,930
| -53% | -$37.6M |
|
|
CERE
442
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $36.3M | 0.03% |
1,151,321
-1,614,599
| -58% | -$45.6M |
|
443
Eagle Materials
EXP
$6.48B
| $36.2M | 0.03% |
272,678
-366,524
| -57% | -$46.3M |
|
444
Rhythm Pharmaceuticals
RYTM
$7.31B
| $36.1M | 0.03% |
1,240,153
-1,882,013
| -60% | -$48.4M |
|
|
SNV
445
DELISTED
Synovus
SNV
| $36M | 0.03% |
958,557
-512,895
| -35% | -$20.4M |
|
446
Cable One
CABO
$237M
| $36M | 0.03% |
50,520
-35,438
| -41% | -$26.4M |
|
|
EGRX
447
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $35.9M | 0.03% |
1,229,872
-1,249,686
| -50% | -$39.7M |
|
448
Nomad Foods
NOMD
$1.78B
| $35.7M | 0.03% |
2,069,964
-2,822,116
| -58% | -$44.7M |
|
449
Steven Madden
SHOO
$3.17B
| $35.6M | 0.03% |
1,114,532
-469,646
| -30% | -$14.7M |
|
450
QuidelOrtho
QDEL
$1.13B
| $35.6M | 0.03% |
415,533
-414,299
| -50% | -$35.1M |
|
Similar funds
Janus Henderson Group's Q4 2022 Portfolio in Review
As of Q4 2022, Janus Henderson Group held 2,666 positions worth $140B, down 48% from $267B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Janus Henderson Group withdrew a net $148B in Q4 2022, closing 210 positions and reducing 1,907 holdings. Its most notable exit was Terminix Global Holdings, Inc., an estimated $901M position sold in full.
By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 30% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Janus Henderson Group opened a new position in Rentokil worth $510M.
- Janus Henderson Group's largest Q4 2022 buy was Rentokil: 16,564,405 shares worth $510M.
- Janus Henderson Group added most to Apellis Pharmaceuticals in Q4 2022, an estimated $210M increase.
- Janus Henderson Group's biggest Q4 2022 reduction was Microsoft, cutting an estimated $8.38B.
- Janus Henderson Group fully exited Terminix Global Holdings, Inc. in Q4 2022, selling an estimated $901M.
- Janus Henderson Group's ten largest holdings make up 22% of its $140B portfolio in Q4 2022.
- Janus Henderson Group opened 131 new positions and closed 210 in Q4 2022.
- Janus Henderson Group's portfolio value fell 48% quarter-over-quarter to $140B.
Based on Janus Henderson Group's 13F filing for Q4 2022, filed 14 Feb 2023.